Nicole Harriott, director of chemistry of Neurocrine Biosciences, prepares a sample at a company lab as part of the drug discovery and development process. Neurocrine banked on the neuroscience, which has paid off. Photo courtesy of Neurocrine Bioscienes

Nicole Harriott, director of chemistry of Neurocrine Biosciences, prepares a sample at a company lab as part of the drug discovery and development process. Neurocrine banked on the neuroscience, which has paid off. Photo courtesy of Neurocrine Bioscienes

— Amid big pharma’s waning commitment to neurological disorders like Alzheimer’s, San Diego startups and midstage biotechs see opportunity...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • NEW: San Diego 500 — influential business leaders you need to know
Yours for only $129